Family with sequence similarity 19 member A5 (FAM19A5) is a secretory protein highly expressed in the brain that regulates ...

In a recently published study, researchers from Shandong Second Medical University and collaborators synthesized a new ...

Researchers from CJ Bioscience Inc. presented the discovery and preclinical characterization of CJRB-201, a novel ...

Eli Lilly and Co. to discover, develop and commercialize molecular glue therapeutics for oncology. “It’s a really important deal, especially given the discovery of Trueglues is something Magnet is ...

The Apple Watch may be able to alert wearers to heart palpitations, but Google LLC’s Pixel Watch 3 can now detect when a user ...

Derm-Biome Pharmaceuticals Inc. has reported findings from a study of its topical drug DB-007-5 in a well-established ...

The BioWorld Biopharmaceutical Index (BBI) ended 2024 down 2.24%, despite hitting a peak of 25.19% in late August. While it ...

To increase diagnosis across Australia, the partnership will see Compumedics Ltd. of Melbourne supply its Somfit devices and electrodes to Philips’ pharmacy-based sleep programs in pharmacies across ...

Nick Decker, directory of global regulatory policy for Roch Holding AG’s Roche Diagnostics division, said the FDA is moving carefully into the PCCP space, and industry, too, is taking a measured ...

Astrazeneca plc’s good news with its oral selective estrogen receptor degrader (SERD) and estrogen receptor antagonist, ...

Researchers from Cedars-Sinai Medical Center presented the preclinical efficacy of KROS-401, an IL-4/IL-13 blocking peptide that effectively reprograms macrophages in glioma models.

BioWorld tracked 171 phase I-III clinical trial updates, down from 212 in December. The month delivered 12 successful phase III outcomes, six of those in cancer, while two trials ended in failure.